SELECTOR: Selective mRNA-LNP Engineering for Cost-Effective in situ CAR T-cell Programming

Kernal Biologics, Inc. in Cambridge, Mass. intends to use a novel lipid nanoparticle-based platform to treat multiple sclerosis and blood cancers.

Back to Award Directory